SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Pharmacological inhibition of the Shh pathway by the Smo antagonist Vismodegib (GDC-0449) was associated with a markedly induced autophagy of CML cells whose simultaneous inhibition potently killed Imatinib-sensitive and -resistant BCR-ABL+ cells [56].